Nephron Pharmaceuticals
A HRSA fiscal year 2023 audit tentatively found that drug maker Nephron Pharmaceuticals owes 340B repayments to providers.

Drug Maker Owes 340B Providers Repayment, HRSA Pending Audit Finds

The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at